Higher Radiation Doses Over Shorter Time Period Is Safe, Effective, Prostate Cancer Trial Shows

Higher Radiation Doses Over Shorter Time Period Is Safe, Effective, Prostate Cancer Trial Shows
Radiation therapy for prostate cancer could be given in higher doses over a shorter period of time, results from a Phase 3 trial show. The treatment, called ultrahypofractionated radiotherapy, calls for patients to receive treatment every other weekday for two-and-a-half weeks, instead of every weekday for eight weeks, as required in conventional fractionated radiation therapy. In addition to using a lower total dose, the treatment was found to be as safe and effective as the standard approach, according to researchers. The findings were presented at the European Society for Radiotherapy and Oncology (ESTRO) 37 Congress, held April 20-24 in Barcelona, Spain. The study, "Ultrahypofractionation for prostate cancer: outcome from the Scandinavian phase 3 HYPO-RT-PC trial," was presented by Prof. Anders Widmark, a senior consultant at Umeå University in Sweden. "We already know that radiotherapy can destroy cancer cells in the prostate and that it has advantages over surgery and hormone therapy because it is less likely to cause impotence or incontinence. However, radiotherapy requires expensive specialist equipment and patients can end up on a waiting list for treatment," Widmark said in a press release. "Ultrahypofractionated radiotherapy offers a number of practical benefits to patients as well as time and cost-savings for hospitals, so we wanted to test if it is as safe and effective as standard radiothe
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *